Sunshine Biopharma Inc Warrant
SBFMW
3 hedge funds and large institutions have $12.3K invested in Sunshine Biopharma Inc Warrant in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
0.16% less ownership
Funds ownership: 0.37% → 0.21% (-0.16%)
25% less funds holding
Funds holding: 4 → 3 (-1)
54% less capital invested
Capital invested by funds: $27K → $12.3K (-$14.7K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.72K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.57K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $12.2K | -$2.57K | -5,376 | -12% |
|
|
2
UBS Group
Zurich,
Switzerland
| $132 | -$4.72K | -9,873 | -96% |
|
3
Bank of America
Charlotte,
North Carolina
| $33 | – | – | – |
|
SBFMW Hedge Fund Activity: Q4 2022 in Review
3 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma Inc Warrant (SBFMW) for Q4 2022, worth a combined $12.3K — down 54% from $27K a quarter earlier.
Fund positioning in SBFMW was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was UBS Group, cutting an estimated $4.72K.
- 3 institutional investors held Sunshine Biopharma Inc Warrant (SBFMW) as of Q4 2022, down from 4 in Q3 2022.
- Funds reported $12.3K of Sunshine Biopharma Inc Warrant stock for Q4 2022, down 54% quarter-over-quarter.
- 0 funds opened new Sunshine Biopharma Inc Warrant positions in Q4 2022 and 0 closed out.
- The largest Sunshine Biopharma Inc Warrant seller in Q4 2022 was UBS Group, an estimated $4.72K sold.
Based on aggregated 13F filings for Q4 2022.